Management of inherited thrombophilia in pregnancy

Laura Ormesher1,2, Louise Simcox1,2, Clare Tower1,2 and Ian A Greer3

Abstract
Adverse pregnancy outcomes, such as pregnancy loss and pre-eclampsia, are associated with thrombotic mechanisms and thrombophilia. Antithrombotic interventions, particularly low-molecular-weight heparin, have been investigated in women identified by previous pregnancy outcome; however, the results have been inconsistent. This may reflect heterogeneity of both the study groups and the disease processes resulting in inadequate stratification to guide antithrombotic interventions. Furthermore, the variation in gestation at initiation of low-molecular-weight heparin treatment might be important. Despite limited evidence of efficacy, low-molecular-weight heparin is often used in an attempt to prevent these complications, owing to the lack of other effective treatments and its perceived safety in pregnancy. Research is required to better understand the disease processes, identify possible biomarkers and thereby more homogeneous groups for targeted treatment.

Keywords
Inherited thrombophilia, pregnancy, low-molecular-weight heparin

Background
Pregnancy is a physiological prothrombotic state. Venous thromboembolism (VTE) is a leading cause of direct maternal death well described in the MBRRACE reports.1 In addition, many adverse pregnancy outcomes, including fetal growth restriction (FGR), pregnancy loss, pre-eclampsia and placental abruption, which collectively affect up to 15% of pregnancies,2 share similar and overlapping micro- and macro thrombotic pathogenic processes. The high physical and psychological burden of such adverse pregnancy outcomes makes the development of targeted and effective preventative interventions a significant issue for obstetric care. Despite limited evidence of benefit, the well-known association between thrombophilias and adverse pregnancy outcomes has led to widespread use of prophylactic low-molecular-weight heparin (LMWH) in pregnancy, as there are few interventions with biological plausibility for an effect.

Physiological prothrombotic changes in pregnancy
Hypercoagulability is a physiological adaptation in pregnancy, reflecting a number of alterations in coagulation and fibrinolytic pathways, which are summarised in Table 1. This hypercoagulant state increases through pregnancy, peaking at term.2,3

The endogenous anticoagulants, activated protein C (APC) and its vitamin K–dependent cofactor protein S, are reduced in pregnancy.4–6 Fibrinolysis is reduced in pregnancy largely due to placenta-derived PAI-2; however, this normalises rapidly post-delivery.7

As pregnancy advances, tissue factor–dependent thrombin generation increases, along with Factors VII, VIII, IX, fibrinogen, prothrombin fragment 1+2 and FDP, while protein C is reduced.8,9

1Department of Obstetrics, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
2Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester, UK
3Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK

Corresponding author:
Laura Ormesher, Department of Obstetrics, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
Email: laura.ormesher@cmft.nhs.uk
thrombin-antithrombin complexes.\textsuperscript{8,9} D-dimer levels increase through pregnancy reflecting the overall changes in coagulation and fibrinolysis in pregnancy.\textsuperscript{9}

The placenta itself has procoagulant characteristics, with high levels of tissue factor expressed in trophoblast cells.\textsuperscript{10} However, there are also inhibitory mechanisms such as endothelial protein C receptor, thrombomodulin, annexin V and tissue factor pathway inhibitor, which increases from the 10th week of pregnancy.\textsuperscript{7,11}

**Inherited thrombophilias**

The most common inherited thrombophilias are Factor V Leiden (FVL) and Factor II (prothrombin) G20210A, which affect 3–11% of the population; less prevalent (<1%) inherited thrombophilias include protein C, protein S and antithrombin deficiency, dysfibrinogenemias and hyperhomocysteinemia.\textsuperscript{12–14}

**FVL**

FVL accounts for 40–50% of inherited thrombophilias, with a prevalence of heterozygosity of 3–8% in the United States and Europe and as high as 8.8% in the white British population.\textsuperscript{15} It is an autosomal dominant condition with incomplete penetrance, characterised by a relative resistance to active Protein C, leading to the inability of Protein C to cleave Factors Va and VIIIa because of a mutation at the cleavage site as a consequence of a single-nucleotide polymorphism. Its clinical expression varies depending on its homo- or heterozygosity and coexisting genetic and acquired disorders and risk factors.\textsuperscript{15}

**Factor II (prothrombin) G20210A heterozygotes**

The prothrombin G20210A polymorphism is a prevalent genetic variant in white populations with incidence of 1–6%. Factor II G20210A increases prothrombin and thus greater thrombin generation and concurrently reduces APC-mediated inactivation of Factor Va.\textsuperscript{16} This in turn leads to a prothrombotic state.

**Protein C deficiency**

Protein C is a vitamin K–dependent natural anticoagulant, which inactivates Factors Va and VIIIa, thereby inhibiting thrombin generation.\textsuperscript{17} Its deficiency can be a result of multiple different genetic mutations, leading to varying degrees of hypercoagulability.\textsuperscript{18}

**Protein S deficiency**

Protein S is a vitamin K–dependent cofactor of protein C, which only cleaves Factors Va and VIIIa in its free form.\textsuperscript{19} Since Protein C anticoagulant activity is dependent on Protein S, deficiency in Protein S is associated with hypercoagulability. Protein S also has Protein C–independent roles, in which it directly inhibits factor Xase and prothrombinase and interacts with tissue factor pathway inhibitor to further inhibit factor Xa.\textsuperscript{20} Its protein C–independent mechanisms are enhanced by LMWH.\textsuperscript{20}

**Antithrombin deficiency**

Antithrombin deficiency can be acquired and inherited; the inherited condition has a prevalence of 1 in 500–5000.\textsuperscript{21} Antithrombin inactivates thrombin and Factor Xa; therefore, its deficiency promotes coagulation.\textsuperscript{21} Quantitative Type I antithrombin deficiency results from heterozygous point mutations or major gene deletions leading to reduction in levels and function of antithrombin.\textsuperscript{22} The more common qualitative Type II is associated with normal antithrombin levels and reduced function and is further categorised into IIa, b or c depending on which part of antithrombin is affected by the mutation.\textsuperscript{21} Antithrombin functional assay is the initial investigation of choice, in order not to miss Type II deficiency. If abnormal, antithrombin antigen levels will distinguish between the two types. Functional assays assessing inhibitory activity on Xa have a higher sensitivity than those assessing thrombin and some patients with Type II antithrombin deficiency have only slightly reduced or even normal function, thus increasing the complexity of its diagnosis.\textsuperscript{21}

**Dysfibrinogenemias**

Congenital dysfibrinogenemias are rare and have an autosomal dominant pattern of inheritance.\textsuperscript{23} They result in defects in the thrombin–fibrinogen reaction, preventing the conversion of soluble fibrinogen into insoluble fibrin. This in turn can lead to thrombosis, bleeding and defective wound healing.\textsuperscript{23}
Hyperhomocysteinemia
different inherited enzyme defects can lead to hyperhomocysteinemia. The most common is a single-nucleotide polymorphism in the methylene tetrahydrofolate reductase gene, MTHFR 677T. Homocysteine, when auto-oxidated, can lead to the production of biologically reactive products and increased cell toxicity. The four consequential disease processes include thrombosis, oxidant stress, apoptosis and cellular proliferation. Folic acid, B12 and B6 supplements reduce circulating homocysteine levels; however, the clinical significance of this has yet to be demonstrated.

Thrombophilia and pregnancy

Data largely from retrospective cohorts and case control studies have shown that inherited thrombophilias are associated not only with VTE but also with adverse pregnancy outcomes including recurrent miscarriage and gestational vascular complications. Initial reports such as that of Kupferminc et al. reported as many as 65% of women with pre-eclampsia, unexpected stillbirth, placental abruption and FGR had some form of thrombophilia. More recent data, including from prospective studies, have demonstrated a more modest association. The evidence is summarised in Table 2. Inherited thrombophilias have also been linked to fertility problems and implantation failure, although no causal relationship has been proven. As the overall effect of inherited thrombophilias on adverse pregnancy is modest, this suggests that their effect is likely to be contributory rather than a primary cause.

Biological plausibility for thrombophilia and pregnancy complications

A satisfactory placental circulation is required for successful pregnancy development. Inadequate placental perfusion may reflect micro thrombotic events, which lead to a reduction in trophoblast invasion and chronic hypoxia. This is thought to prompt gestational vascular complications including FGR, late pregnancy loss, placental abruption and pre-eclampsia, which affect up to one in six pregnancies. It is therefore logical to consider that prothrombotic conditions, including the inherited thrombophilias discussed in this review, could lead to an increased risk in such pregnancy complications. There are a number of examples, which demonstrate this biological plausibility in animal models.

The pathogenesis underlying the epidemiological and theoretical association between thrombophilias and adverse pregnancy outcomes has been studied. For example, Isermann et al. studied mice with a disrupted gene coding for thrombomodulin. At the feto-maternal interface, thrombomodulin deficiency was associated with embryo abortion. This study demonstrated the essential role of thrombomodulin in trophoblast growth and survival. At the feto-maternal interface, thrombomodulin deficiency stimulates a procoagulant cascade, thereby precipitating giant trophoblast cell death and arrest of growth of trophoblast cells.

A report of mice with FVL highlighted the synergistic effect of both maternal and fetal thrombophilic mutations. They found that FVL mice with fetal gene defects experienced fetal loss. This study also demonstrated that fetal loss was secondary to Par4-mediated platelet activation, interestingly in the absence of overt thrombosis. This has demonstrated the high-risk pregnancy model of concurrent fetal and maternal thrombophilia as well as a haemostatic pathogenesis independent of thrombosis.

The study by Jianzhong et al. further complicated the role of thrombophilia and LMWH in recurrent pregnancy loss. The protective effect of LMWH on murine pregnancies was not reciprocated by fondaparinux, despite its comparable anticoagulant effect. This has highlighted a potential anticoagulant-independent effect of LMWH on placental development and the heterogeneity of placental-mediated complications.

Early pregnancy loss

Heritable thrombophilias are associated with early pregnancy loss. A systematic review reported that

| Factor | VTE | Early pregnancy loss | Recurrent first-trimester loss | Second-trimester loss | Late pregnancy loss | Pre-eclampsia | Placental abruption | FGR |
|--------|-----|----------------------|-----------------------------|-----------------------|-------------------|---------------|-------------------|-----|
| V Leiden | ↑ | ↑ | ↑/←→ | ↑ | ↑ | ↑ | ←→ | ←→ |
| G20210A | ↑ | ↑ | ↑/←→ | ↑ | ↑ | ↑ | ←→ | ←→ |
| Protein C deficiency | ↑ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ |
| Protein S deficiency | ↑ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ |
| Antithrombin deficiency | ↑ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ |
| Hyperhomocysteinemia | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ | ←→ |

Data taken from Robertson et al. and Rey et al. VTE: venous thromboembolism; FGR: fetal growth restriction.
homozygotes for FVL and heterozygotes for FVL and prothrombin G20210A are at increased risk of early pregnancy loss (odds ratio (OR) 2.71 (95% confidence interval (CI) 1.32–5.58), 1.49 (95% CI 1.09–2.58) and 2.49 (95% CI 1.24–5.00), respectively.26 The other inherited thrombophilias showed no association with early pregnancy loss.

**Recurrent first-trimester loss**

There are modest associations between recurrent first-trimester loss and prothrombin G20210A heterozygosity, and with FVL (OR 2.70 (95% CI 1.37–1.69) and 1.91 (95% CI 1.01–3.61), respectively).26 Such a weak association would again be consistent with thrombophilia being a contributory factor rather than a single cause of such complications.

**Second- and third-trimester pregnancy loss**

FVL and prothrombin G20210A heterozygotes have a stronger association with second-trimester loss than other early pregnancy loss (OR 4.12 (95% CI 1.93–8.81) and 8.60 (95% CI (0.44–1.69), respectively).26 This was consistent with an earlier systematic review, which reported the strongest association to be between FVL and pregnancy loss after 19 weeks.28 Rodger et al.’s34 updated meta-analysis in 2014 looked at pregnancy loss irrespective of gestation and similarly found patients with FVL to be at increased risk (risk ratio 1.79 (95% CI 1.06–3.03)); it did not, however, find associations between prothrombin G20210A heterozygotes and overall pregnancy loss. Fewer studies exist for Protein C and S deficiency and poor pregnancy outcomes; however, Robertson’s systematic review demonstrated a significant association between Protein S deficiency and late pregnancy loss although confidence intervals were wide reflecting small numbers (OR 20.1 (95% CI 3.70–109.15)).26 There was no association with Protein C deficiency.

**Pre-eclampsia**

There is a modest association between FVL heterozygosity, prothrombin 20210A and MTHFR C677T homozygotes.26 However, this was not confirmed in the systematic review of prospective studies.35

**Placental abruption**

Only two inherited thrombophilias have demonstrated statistically significant associations with risk of placental abruption; these are FVL heterozygotes and prothrombin G20210A heterozygotes.26 Again, however, no association was found on meta-analysis of prospective studies.35

**FGR**

Although a generalised association between thrombophilia and FGR was demonstrated in a meta-analysis of five studies, meta-analyses of individual inherited thrombophilias demonstrated no significant association.22,35

**VTE**

VTE is a leading cause of direct maternal death1 and thrombophilia is an established risk factor. For this reason, appropriate risk stratification and prophylaxis is crucial in women with thrombophilia in pregnancy. A systematic review demonstrated a relative increase in VTE risk in all inherited thrombophilias except homozygotes for MTHFR C677T; one explanatory hypothesis is that routinely taken folic acid supplements reduce homocysteine levels, thus reducing an increased VTE risk.26 In contrast, the highest relative risk of VTE was associated with homozgyous FVL (34.4%), translating to an absolute risk of 3.4%.26 The more common thrombophilias demonstrated a weaker association. Early reports on the risk of VTE associated with deficiencies of antithrombin, Protein C and Protein S may have overestimated the risk due to methodologic limitations such as selection bias in family studies36,37 as more recent estimates suggest a much lower level of risk.38 A significant risk factor is family history of VTE, irrespective of thrombophilia; this increases risk twofold to fourfold.39

**Current guidance**

The lack of a strong and consistent evidence base to underpin clinical guidelines leads to differing recommendations in clinical guidelines such as from the American College of Chest Physicians (ACCP)38 compared with the Royal College of Obstetricians and Gynaecologists (RCOG) guideline on thromboprophylaxis40 (Tables 3 and 4).

Given the weaker association between the more common thrombophilias and VTE and the significant risk factor of positive family history, the ACCP guideline recommends LMWH prophylaxis in two groups of women: (1) with no family history of VTE who are either homozygotes of FVL or prothrombin gene mutations; or (2) women with family history of VTE in combination with any other inherited thrombophilia.38 The ACCP guideline does not recommend prophylactic LMWH use for those with inherited thrombophilias in the absence of previous pregnancy complications. This is justified by the lack of the existing evidence for improvement in pregnancy outcome by LMWH in women with inherited thrombophilias and recurrent pregnancy loss.38 However, the ACCP guideline does recommend aspirin for those who are at high risk of pre-eclampsia, irrespective of thrombophilia history. This is in-keeping with the American Congress of Obstetricians and Gynecologists (ACOG)41 and supported by a strong evidence base.42
The RCOG guidelines similarly recommend ‘consideration’ of antenatal LMWH prophylaxis in asymptomatic patients with homozygosity for FVL and prothrombin G20210A. This guideline also recommends consideration of LMWH prophylaxis in women with antithrombin, Protein C or Protein S deficiency, despite the absence of family/personal history of VTE, which differs from the ACCP guidance. The RCOG guideline further stratifies risk by pragmatic accumulation of risk factors: if heterozygosity for FVL or prothrombin gene mutation is present with two or three other risk factors, or there is compound heterozygosity, prophylactic LMWH can be given antenatally. Another difference between the two guidelines is that the RCOG guideline applies risk stratification to dosing differences, suggesting that women with antithrombin deficiency and previous VTE should have 50–100% treatment dose antenatally and for 6 weeks postnatally.

ACCP and RCOG are just two examples of internationally available guidelines. The variation between these two guidelines alone exemplifies the lack of an adequate evidence base.

### Table 3. Recommendations for thromboprophylaxis for women with inherited thrombophilia in pregnancy.

| History of VTE                  | Inherited thrombophilia | Antenatal management | Postnatal management |
|---------------------------------|-------------------------|----------------------|----------------------|
| Previous VTE                   | Antithrombin deficiency | 50–100% treatment dose LMWH | 50–100% treatment dose LMWH × 6 weeks/until oral (PO) anticoagulation started |
| Asymptomatic                    | Antithrombin deficiency | Involve haematologist Anti-Xa monitoring | Prophylactic dose LMWH |
| Protein C deficiency            | All others              | Consider prophylactic dose LMWH | Prophylactic dose LMWH × 6 weeks |
| Protein S deficiency            | Homozygous FVL          | If more than one thrombophilic defect, consider prophylactic dose LMWH | If more than one thrombophilic defect, for prophylactic dose LMWH × 6 weeks |
| Compound heterozygotes          | Homozygous prothrombin gene mutation | | |
| Homozygous FVL                  | Heterozygous FVL        | Consider prophylactic dose LMWH in the presence of three other risk factors/ from 28 weeks if two other risk factors | Prophylactic dose LMWH × 10 days if one other risk factor |
| Heterozygous prothrombin gene mutation | | | |

Data taken from RCOG Green-top guideline no. 37a.

VTE: venous thromboembolism; LMWH: low-molecular-weight heparin; FVL: Factor V Leiden.

### Table 4. ACCP guidelines for thromboprophylaxis for women with inherited thrombophilia in pregnancy.

| History of VTE/pregnancy complication | Inherited thrombophilia | Antenatal management | Postnatal management |
|---------------------------------------|-------------------------|----------------------|----------------------|
| Previous VTE                          | Any inherited thrombophilia | Prophylactic or intermediate dose LMWH | Prophylactic or intermediate dose LMWH × 6 weeks |
| Asymptomatic but has family history of VTE | Homozygous for Factor V Leiden | Prophylactic or intermediate dose LMWH | Prophylactic or intermediate dose LMWH or vitamin K antagonists (INR 2-3) × 6 weeks |
|                                       | Homozygous for prothrombin gene mutation | Prophylactic or intermediate dose LMWH | Prophylactic or intermediate dose LMWH or vitamin K antagonists (INR 2-3) × 6 weeks |
|                                       | Protein C or S deficiency | Thromboprophylaxis not recommended | Prophylactic or intermediate dose LMWH × 6 weeks |
|                                       | All other inherited thrombophilias | Thromboprophylaxis not recommended | Prophylactic or intermediate dose LMWH or vitamin K antagonists (INR 2-3) × 6 weeks |
| Asymptomatic and no family history of VTE | Any inherited thrombophilia | Thromboprophylaxis not recommended | Thromboprophylaxis not recommended |
| Previous pregnancy complications      | Any inherited thrombophilia | Thromboprophylaxis not recommended | Thromboprophylaxis not recommended |
| High risk of pre-eclampsia            | Irrespective of thrombophilia history | Low-dose aspirin from second trimester | Thromboprophylaxis not recommended |

Data taken from Bates et al.

ACCP: American College of Chest Physicians; VTE: venous thromboembolism; LMWH: low-molecular-weight heparin; INR: international normalised ratio.
Discussion

There is an evidence base for management of VTE, in part, extrapolated from the non-pregnant population; however, the evidence base is limited for adverse pregnancy outcomes as discussed above. Due to the safety and relatively low side-effect profile of low-dose aspirin (LDA) and LMWH, as shown in Table 5,43,44 the biological plausibility for an effect, extrapolation from Antiphospholipid syndrome (APS)45 and the lack of alternative interventions, they have been introduced into care of groups at high risk of adverse pregnancy outcome in advance of evidence. Indeed, in three major randomised trials in women selected on the basis of previous pregnancy complications alone (rather than thrombophilia), such treatment was ineffective.46–48 Interestingly, however, the trials from Gris et al.49,50 on prevention of adverse pregnancy outcomes in women with a history of pre-eclampsia and abruption treated with LMWH showed significant benefit from LMWH. Of note, the women studied had a higher prevalence of thrombophilia (ca. 15%). In these randomised controlled trials, the pre-eclampsia rate was 5.8% with LMWH compared with 16.7% in the controls, and the incidence of severe pre-eclampsia was also significantly reduced in the LMWH cohort with a rate of 0.9% compared with 7.1%.49 In women with a past history of abruption, the composite outcome of at least one of pre-eclampsia, placental abruption, birth weight under the fifth centile and fetal loss after 20 weeks was significantly lower in the LMWH group (12.5% compared with 31.3%).50

Furthermore, meta-analysis of six trials in this area is also consistent with some evidence of benefit from LMWH. In this meta-analysis, the study population was not specific to thrombophilia, but included pregnant women who had previous pregnancy complications including pre-eclampsia, placental abruption, small for gestational age (SGA) (<10th centile), second- and third-trimester pregnancy loss,51 there was a significant reduction in the recurrence rate (18.7% in the LMWH group, versus 42.9% in the controls, relative risk reduction, 0.52; 95% CI 0.32–0.86). They had similarly positive secondary outcomes with pre-eclampsia, SGA and preterm delivery. This demonstrates the potential for LMWH to be of value for women with previous placenta-mediated pregnancy complications, but requires corroboration with high-quality multicentre studies.

For women with a thrombophilia and history of adverse pregnancy outcome, this is an emotive area. Clinicians have no proven effective treatment, yet there is demand from patients for an intervention that might help. Clinicians are therefore obliged to actively manage such risk factors, despite the lack of good quality evidence supporting this. Although an increase in relative risk of VTE and adverse pregnancy outcomes has been demonstrated in the literature for those with inherited thrombophilias, the absolute risk is often low and the interventions are costly and do not come without risk. It is therefore important to consider the limited evidence behind these interventions.

For women with heritable thrombophilia, small non-randomised trials and observational studies have suggested some benefit.8 However, this contrasts with data from recently reported randomised trials. The TIPPS trial studied women with thrombophilia and previous placenta-mediated pregnancy complications or VTE in a randomised trial of 146 women assigned to antepartum LMWH versus 143 assigned to no antepartum LMWH. There was a higher proportion of LDA use in the control group (40% versus 30%).52 Given the fact that LDA has not previously been shown to be of benefit in such women, the difference in LDA use in the two groups should not affect the reliability of the data.45 The trial demonstrated no significant reduction in adverse pregnancy outcome with LMWH treatment.52 With regard to safety, major bleeding did not differ between the two groups, but minor bleeding was more common in the LMWH group (risk difference 10.4%, 95% CI 2.3–18.4; p=0.01).

The FRUIT trial studied LMWH intervention in 139 women with inherited thrombophilia and a history of previous early-onset gestational hypertensive disorder.53 In contrast to the TIPPS trial, it only recruited patients at less

| Complication                        | Greer and Nelson-Piercy43   | Nelson-Piercy et al.44 |
|------------------------------------|-----------------------------|------------------------|
|                                    | Systematic review           | Retrospective study    |
| Rate % (n=2777)                    | Rate % (n=1267)             |
|------------------------------------|-----------------------------|------------------------|
| VTE (overall)                      | 0.86                        | 1.19                   |
| VTE recurrence on treatment        | 1.15                        | 1.97                   |
| Bleeding                           | Significant bleeding: 1.98  | PPH > 500 = <1000 mL: 11 |
|                                   | (1.50–2.57)                 | PPH > 1000 ≈ <1500 mL: 0.9 |
|                                   |                             | PPH > 1500 mL:1.1      |
| Wound haematoma                    | 0.61                        | 0.9                    |
| Heparin-induced thrombocytopenia   | 0.00                        | 0                      |
| Osteoporosis                       | 0.04                        | 0.2                    |

LMWH: low-molecular-weight heparin; VTE: venous thromboembolism; PPH: postpartum haemorrhage.
than 12 weeks gestation and all patients received LDA. A significant reduction in hypertensive disease recurrence before 34 weeks gestation was demonstrated in women treated with LMWH and LDA compared with LDA alone, with a risk reduction of 8.7% (CI 1.9–15.5%; \( p = 0.012 \)). However, the overall hypertensive disease recurrence rate was unchanged with no difference in maternal or fetal outcome with no significant difference in gestation at delivery, only a reduction in antenatal steroid use in the LMWH group consequent upon the reduction in recurrence before 34 weeks of gestation.

Given the biological plausibility for a thrombotic mechanism and the potential for LMWH to impact on this, it is important to consider whether LMWH might still have a role in this disease process following the reports of the TIPPS and the FRUIT trials. There are data that show potential benefit from LMWH treatment on implantation and placental development including some data that suggest benefit on pregnancy outcome from LMWH in assisted conception treatment.\(^8\) This leads to the hypothesis that the pathogenic processes originate in the first trimester. If this is the case, it is important to consider the timing of treatment in relation to implantation. In the TIPPS trial, less than 30% were recruited before 8 weeks’ gestation.\(^52\) This highlights the need to examine LMWH administration in the peri-implantation period.

Furthermore, similarities between the different placenta-mediated complications, including deficient implantation and placental infarction, have led to the theory that they share the same haemostatic pathological processes\(^8\) and would therefore benefit from the same intervention. Perhaps this is naïve as different disease mechanisms may be operating. Due to the complex multifactorial aetiologies of such outcomes and the heterogeneity of women studied in previous trials, it is possible that more convincing evidence for successful intervention may unfold if further research is targeted better through a disease process-specific approach.\(^8\) This highlights the need for further research into the underlying disease mechanisms to allow better patient stratification, with a precision medicine approach allowing clinical trials to target more homogeneous populations with a disease process amenable to an antithrombotic intervention.

Such trials are not easy as evidenced by the TIPPS trial, which took 12 years to complete with centres in several countries.\(^51\) Therefore, to recruit sufficient numbers of women with well-characterised disease mechanisms for a precision medicine trial will likely require a multi-centre international collaboration. Such an approach with a more homogeneous patient group is underway with the ALIFE 2 trial, which is randomising pregnant women of less than 7 weeks’ gestation and confirmed inherited thrombophilia with a history of two or more miscarriages or intra-uterine fetal deaths, or both to LMWH plus standard pregnancy surveillance versus standard pregnancy surveillance alone (www.ALIFE2study.org).

**Conclusion**

The widespread use of prophylactic anticoagulant and anti-platelet therapy for women with thrombophilia and a history of adverse pregnancy outcome based on the logical association between thrombotic processes and these complications has overridden the paucity of data supporting this treatment. Despite some studies demonstrating potential benefit of LMWH in women with previous placenta-mediated complications, there is as yet no good quality evidence supporting its antenatal use in those with inherited thrombophilia.

This lack of evidence may reflect the multifactorial nature of these complications, heterogeneity of the study groups with inadequate stratification or the variation in gestation at which LMWH has been introduced in these studies. Acquiring such evidence is not easy. The TIPPS trial clearly demonstrates the difficult and lengthy process. In the meantime, clinicians and patients will need guidance on the management of these conditions based on the current evidence including the need to continue to pursue clinical trials in this area. Only with research to provide a better understanding of the disease processes, identification of possible biomarkers and better-targeted treatment can we guide clinical decision making in this important and emotive area.

**Future perspective**

In 5 years, precision medicine, which is already widely used in cancer care, will hopefully have been introduced into obstetrics. With progressing research into the pathophysiology of adverse pregnancy outcomes and potential biomarkers, we should have sufficient knowledge for categorisation and risk stratification of adverse pregnancy outcomes by their disease process rather than their clinical outcome. Randomised trials of interventions targeted on specific disease processes will accumulate to create a sounder evidence base to better inform management in this complex area.

**Executive summary**

- Pregnancy is a physiological prothrombotic state.
- VTE is a leading cause of direct maternal death.
- Adverse pregnancy outcomes, including FGR, pregnancy loss, pre-eclampsia and placental abruption, share similar micro- or macro thrombotic pathogenic processes.
- Heritable thrombophilia is associated with both gestational VTE and adverse pregnancy outcomes.
- The association between heritable thrombophilia and poor pregnancy outcomes has led to widespread use of prophylactic LMWH based on the safety of LMWH, biological plausibility for benefit and lack of alternative interventions.
• Trials of intervention with LMWH for adverse pregnancy outcomes show inconsistent results with no overall evidence of a major benefit, including women with both heritable thrombophilia and a history of previous adverse pregnancy outcome.
• The inconsistent evidence base may reflect the multifactorial nature of these complications and heterogeneity of the study groups with inadequate stratification, or the variation in gestation at which LMWH has been introduced in these studies.
• Research is required to provide a better understanding of the disease processes, identify possible biomarkers to guide treatment and examine the possible benefits of better-targeted antithrombotic treatment.

Acknowledgements
The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties. No writing assistance was utilised in the production of this manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.

References
1. Knight M, Kenyon S, Brocklehurst P. (eds) on behalf of MBRRACE-UK. Saving lives, improving mothers’ care: lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009–12. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2014, www.npeu.ox.ac.uk/mbrrace-uk
2. Wilcox AJ, Weinberg CR, O’Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189–194.
3. Huissoud C, Carrabin N, Benchaib M, et al. Coagulation assessment by rotation thromboelastometry in normal pregnancy. Thromb Haemost 2009; 101: 755–761.
4. Cumming AM, Tait RC, Fildes S, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725–727.
5. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166–1170.
6. Faught W, Garner P, Jones G, et al. Changes in protein C and S levels in normal pregnancy. Am J Obstet Gynecol 1995; 172: 147–150.
7. Greer IA, Aharon A, Brenner B, et al. Coagulation and placentamediated complications. Rambam Matimonides Med J 2014; 5(4): e0034.
8. Greer IA, Brenner B and Gris JG. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Brit J Haemat 2014; 165: 585–599.
• Provides a comprehensive review of existing evidence, whilst highlighting the need for precision medicine.
9. Scecs PB, Jorgensen M, Klainbard A, et al. Haemostatic reference intervals in pregnancy. J Thromb Haemost 2010; 103: 718–727.
10. Aharon A, Brenner B, Katz T, et al. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental haemostasis. J Thromb Haemost 2004; 92: 776–786.
11. Aharon A, Lanir N, Drugan A, et al. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost 2005; 3: 2355–2357.
12. Bruce A and Massicotte MP. Thrombophilia screening: whom to test? Blood 2012; 120(7): 1353–1355.
13. Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of risk conferred by factor V Leiden and thrombolytic methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20(1): 266–270.
14. Lindqvist PG, Svensson P and Dahlback B. Activated protein C resistance – in the absence of factor V Leiden – and pregnancy. J Thromb Haemost 2006; 4(2): 361–366.
15. Kuyovich JL, Factor V Leiden thrombophilia. Genet Med 2011; 13(1): 1–16.
16. Aiach M and Emmerich J. Thrombophilia genetics. In: Colman RW, Mander VJ, Clowes AW, et al. (eds) Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 779 pp, 2006.
17. Griffin JH, Fernandez JA, Gale AJ, et al. Activated protein C. J Thromb Haemost 2007; 1: 73–80.
18. Goldenberg NA and Manco-Johnson MJ. Protein C deficiency. Haemophilia 2008; 14(6): 1214–1221.
19. Rezende SM, Simmonds RE, Lane DA, et al. Coagulation, inflammation and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103(4): 1192–1201.
20. Garcia de Frutos P, Fuentes-Prior P, Hurtado B, et al. Molecular basis of protein S deficiency. Thromb Haemost 2007; 98(3): 543–556.
21. Patnaik MM and Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229–1239.
22. Mitton BA and Steineck A. Antithrombin deficiency. Medscape 2014, http://emedicine.medscape.com/article/198573-overview (accessed 21 September 2015).
23. Rocha E, Paramo JA, Aranda A, et al. Congenital dysfibrinogenemias: a review. Ric Clin Lab 1985; 15(3): 205–229.
24. Maron BA and Loscalzo J. The treatment of hyperhomocysteinemia. Ann Rev Med 2009; 60: 39–54.
25. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567–1577.
26. Robertson L, Wu O, Langhome P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171–196.

- Comprehensive systematic review of thrombophilia in pregnancy.

27. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 240: 9–13.

28. Rey E, Khan SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361(9361): 901–908.

29. Nelson SM and Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update 2008; 14(6): 623–645.

30. Berg CJ, Atrash HK, Koonin LM, et al. Pregnancy-related mortality in the United States, 1987–1990. Obstet Gynecol 1996; 88: 161–167.

31. Iserrmann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9(33): 331–337.

32. Sood R, Zogg M, Westrick RJ, et al. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Ecp Med 2007; 204(5): 1049–1056.

33. Jianzhong A, Waitara MS, Bordas M, et al. Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model. Blood 2013; 121(1): 2127–2134.

34. Rodger MA, Walker MC, Smith GN, et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. Thromb Haemost 2014; 12: 469–478.

- Large prospective cohort study showing no association between factor V Leiden or prothrombin gene mutation and placenta-mediated complications.

35. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7(6): e1000292.

- Major systematic review of prospective studies of thrombophilia in pregnancy.

36. Conard J, Horellou MH, Vandreden P, et al. Thrombosis and pregnancy in congenital deficiencies in At-III, protein-C or protein-S – study of 78 women. Thromb Haemost 1990; 63: 319–320.

37. DeStefano V, Leone G, Mastrangelo S, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin-III, protein-C, protein-S. Thromb Haemost 1994; 71: 799–800.

38. Bates SM, Greer IA, Middlesdrop S, et al. VTE, thrombophilia, antithrombotic therapy and prevention of thrombosis. 9th ed: College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl.): e351S–418S

- Provides comprehensive review of evidence base and evidence based guidelines for management of VTE and use of antithrombotic interventions in adverse pregnancy outcomes.

39. Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169(6): 610–615.

40. Green-top guideline no. 37a. London: Royal College of Obstetricians and Gynaecologists, 2015.

41. American College of Obstetricians and Gynecologists. Hypertension in Pregnancy. Obstet Gynecol. 2013; 122(5): 1122–1131.

42. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.

43. Greer IA and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106(2): 401–407.

44. Nelson-Piercy C, Powrie R, Borg JY, et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol 2011; 159(2): 293–299.

45. Gibson PS and Nerenberg KA. TIPPping practice away from anticoagulation in pregnancy. Lancet 2014; 384: 1648–1649.

46. Clark P, Walker ID, Langhorne P, et al. Scottish Pregnancy Intervention Study (SPIN) Collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicentre randomized controlled trial of low-molecular-weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010; 115(21): 4162–4167.

47. Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362(17): 1586–1596.

48. Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119: 3269–3275.

49. Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011; 106: 1053–1061.

50. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abortion placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 771–779.

51. Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014; 123: 822–828.

52. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384(9955): 1673–1683.

53. De Vries JI, van Pampus MG, Hague WM, et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10: 64–72.